40% off all research productsUse codeSOFTLAUNCHApply & shop →
Early human data Brain and Cognitive Health

DSIP

Also called Delta sleep-inducing peptide; emideltide

An experimental nine-amino-acid peptide whose name is more confident than its evidence. Small studies on sleep conflict, and it is not an established insomnia treatment.

Overview

What it is

A nonapeptide investigated in sleep research. FDA notes inconsistencies in the identity of products sold under these names.

How it works

The mechanism is not well established. Studies looked at sleep architecture, sleep pressure and time to fall asleep.

What the research shows

A 1981 six-person infusion study reported increased sleepiness and sleep changes. A 1992 double-blind study in chronic insomnia found mixed changes across measures. A 1987 crossover trial found differences that were already present at baseline and no change in deep or REM sleep. A 1998 open trial looked at opioid withdrawal.

Studied for

  • Chronic insomniasmall, conflicting trials
  • Opioid withdrawalopen study

Safety and regulatory status

Safety and side effects

FDA's 2026 review describes headache, nausea, vertigo and low blood pressure in older IV studies, no safety data for injection under the skin, and aggregation, impurity and immune-reaction concerns. "Non-addictive" and "safe with sleep medicines" are not established.

Regulatory status

Not FDA approved. Reviewed by FDA's compounding advisory committee in July 2026.

Mixing and dosing reference

Reference information only. Read before using this section.
Reference information only. Not instructions. These mixing and dosing figures summarize published studies and third-party protocols so you can understand the research. They are not medical advice, not a recommendation that anyone use any substance, and not a treatment plan. They do not apply to Research Products, which are for laboratory research only and must never be used in humans or animals. Never self-administer any compound. Only a licensed healthcare professional who has evaluated you can decide whether a medication is appropriate and how it should be used.
Choose vial size

DSIP (10 mg Vial) Dosage Protocol

Vial
10 mg DSIP
Add diluent
3 mL
Concentration
3.33 mg/mL
1 unit (U-100)
33.33 mcg in 0.01 mL
Route
Subcutaneous
Typical range
100–300 mcg once daily in the evening (gradual titration).

Standard / Gradual Approach

WeekDaily Dose (mcg)Units (per injection) (mL)
Week 1100 mcg3 units (0.03 mL)
Week 2150 mcg5 units (0.05 mL)
Week 3200 mcg6 units (0.06 mL)
Weeks 4–8250–300 mcg8–9 units (0.08–0.09 mL)

How to mix

  1. Draw 3.0 mL bacteriostatic water with a sterile syringe.
  2. Inject slowly down the vial wall; avoid foaming.
  3. Gently swirl/roll until dissolved (do not shake).
  4. Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.

Protocol source: PeptideDosages.com

Common questions

Does DSIP help with sleep?

Results are inconsistent and mostly from small, old studies. CBT-I is the usual first treatment for long-term insomnia.

How quickly does it work?

No reliable timeline exists.

Can it treat opioid withdrawal?

Only an open study exists. Evidence-based options include buprenorphine, methadone and naltrexone.

Related in Brain and Cognitive Health

Sources and further reading (6)
  1. Schneider-Helmert D. DSIP in severe chronic insomnia. Eur Neurol, 1987.
  2. Bes F, et al. DSIP in chronic insomniac patients: double-blind study. Neuropsychobiology, 1992.
  3. Monti JM, et al. DSIP efficacy in chronic insomniacs, 1987.
  4. FDA. Emideltide bulk drug substances: briefing, July 2026.
  5. NHLBI. Insomnia: treatment.
  6. Source summary: PeptideDosages.com research overview (rewritten for NVO).

Laboratory research material: DSIP Research Use Only

Educational information only. This content summarizes published research for general education. It is not medical advice, not a recommendation to use any substance, and not an instruction for human or animal use. It does not describe any Research Product sold on this site.